PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal with Jupiter Neurosciences
PharmAla Biotech has signed a term sheet to license exclusive U.S. rights of its ALA-002 MDMA therapy candidate to Jupiter Neurosciences in a deal potentially worth over $100 million, including upfront payments and future milestones.
Topics: Licensing Deals MDMA Therapy Pharmaceuticals Psychedelics